Fenfluramine HCl (Fintepla®) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective: Fenfluramine has been shown to provide clinically meaningful and statistically significant reductions in convulsive seizure frequency in children and adolescents (aged 2‐18 years) with Dravet syndrome in two randomized, placebo‐controlled clinical trials. The objective of this analysis was to assess longer‐term safety and efficacy of fenfluramine in patients who completed one of the double‐blind studies and entered an open‐label extension (OLE) study. Methods: Patients enrolling in the OLE study initiated fenfluramine at 0.2 mg/kg/d regardless of their treatment assignment in the double‐blind study. After 4 weeks, the fenfluramine dose could be titrated based on efficacy and tolerability to maximum of 0.7 mg/kg/d (absolute maximum 27 mg/d) or maximum of 0.4 mg/kg/d (absolute maximum 17 mg/d) in patients receiving concomitant stiripentol. The number and type of seizures were recorded daily in an electronic diary, and safety, including echocardiography, was assessed at Months 1, 2, and 3, and at 3‐month intervals thereafter. Results: A total of 232 patients were enrolled as of March 13, 2018. During this analysis period, patients were treated for a median 256 days (range = 46‐634 days). Over the entire OLE analysis period, the median decrease in convulsive seizure frequency compared to baseline in the double‐blind studies was −66.8% (range = −100% to 234.9%; P < .001). The median reduction in seizure frequency was similar in patients <6 (−75.7%) and ≥6 years old (−64.7%). The most commonly reported adverse events included pyrexia (21.6%), nasopharyngitis (19.4%), and decreased appetite (−15.9%). No valvular heart disease (VHD) or pulmonary arterial hypertension (PAH) was observed. Significance: Study results demonstrate that fenfluramine provides clinically meaningful (≥50%) seizure frequency reduction over an extended period in patients with Dravet syndrome. No patient developed VHD or PAH, and fenfluramine was generally well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Lagae, L., Sullivan, J., Knupp, K., Laux, L., Polster, T., Nikanorova, M., Devinsky, O., Cross, J. H., Guerrini, R., Talwar, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32500-0 · Cited by 384
Self-citationNabbout, R., Mistry, A., Zuberi, S., Villeneuve, N., Gil-Nagel, A., Sanchez-Carpintero, R., Stephani, U., Laux, L., Wirrell, E., Knupp, K., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.4113 · Cited by 251
Self-citationSuccessful use of fenfluramine as an add‐on treatment for Dravet syndrome
Ceulemans, B., Boel, M., Leyssens, K., Van Rossem, C., Neels, P., Jorens, P. G., & Lagae, L. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03495.x · Cited by 210
Self-citationA long‐term follow‐up study of Dravet syndrome up to adulthood
Akiyama, M., Kobayashi, K., Yoshinaga, H., & Ohtsuka, Y. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02466.x · Cited by 192
Cited by
Knupp, K. G., Scheffer, I. E., Ceulemans, B., Sullivan, J. E., Nickels, K. C., Lagae, L., Guerrini, R., Zuberi, S. M., Nabbout, R., Riney, K., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0829 · Cited by 137
Self-citationKnupp, K. G., Scheffer, I. E., Ceulemans, B., Sullivan, J., Nickels, K. C., Lagae, L., Guerrini, R., Zuberi, S. M., Nabbout, R., Riney, K., et al. (2023) · Epilepsia · doi:10.1111/epi.17431 · Cited by 55
Self-citationPalmer, E. E., Howell, K., & Scheffer, I. E. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01133-3 · Cited by 53
Self-citationGuerrini, R., Specchio, N., Aledo‐Serrano, Á., Pringsheim, M., Darra, F., Mayer, T., Gil‐Nagel, A., Polster, T., Zuberi, S. M., Lothe, A., et al. (2022) · Epilepsia Open · doi:10.1002/epi4.12624 · Cited by 45
Self-citation
Metadata
- Authors
- Sullivan, J., Scheffer, I. E., Lagae, L., Nabbout, R., Pringsheim, M., Talwar, D., Polster, T., Galer, B., Lock, M., Agarwal, A., Gammaitoni, A., Morrison, G., & Farfel, G.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2020-10-19
- Volume
- 61
- Issue
- 11
- Pages
- 2396-2404
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W3093102068
- Cited by
- 69
- References
- 6
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fenfluramine HCl (Fintepla®) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study. https://app.cochat.ai/papers/10.1111/epi.16722
- The paper
- Sullivan, J., Scheffer, I. E., Lagae, L., Nabbout, R., Pringsheim, M., Talwar, D., Polster, T., Galer, B., Lock, M., Agarwal, A., Gammaitoni, A., Morrison, G., & Farfel, G. (2020). Fenfluramine HCl (Fintepla®) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study. Epilepsia. https://doi.org/10.1111/epi.16722
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.